Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001958440 | SCV002217915 | uncertain significance | not provided | 2024-01-02 | criteria provided, single submitter | clinical testing | This variant, c.45_65dup, results in the insertion of 7 amino acid(s) of the GSN protein (p.Ala17_Leu23dup), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with GSN-related conditions. ClinVar contains an entry for this variant (Variation ID: 1446163). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002331512 | SCV002636506 | uncertain significance | Inborn genetic diseases | 2023-07-03 | criteria provided, single submitter | clinical testing | The c.45_65dupCCTGGCGCTGTGCGCGCTGTC (p.L23_P24insLALCALS) alteration is located in exon 1 (coding exon 1) of the GSN gene. The alteration consists of an in-frame duplication of 21 nucleotides from position 45 to 65, resulting in the duplication of 7 residues. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002497842 | SCV002777900 | uncertain significance | Finnish type amyloidosis | 2022-04-14 | criteria provided, single submitter | clinical testing |